Polycystic Ovary Syndrome and the Potential for Nanomaterial-Based Drug Delivery in Therapy of This Disease

The document explores the potential of nanomaterial-based drug delivery systems for treating Polycystic Ovary Syndrome (PCOS), a complex disorder involving hyperandrogenism, insulin resistance, and inflammation. Current treatments have side effects, but nanomaterials like liposomes, chitosan nanoparticles, and metal nanoparticles (e.g., selenium and silver) offer targeted delivery, enhanced bioavailability, and reduced toxicity. These systems can improve drug stability and efficacy, reduce inflammation, and address metabolic and ovarian dysfunctions. Despite promising advancements, further research is needed to assess nanoparticle toxicity and transition these technologies from lab to clinical use.